Study summary · research use only
Off-Label Use of Teriparatide in Spine
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review summarizes preclinical and clinical findings on off-label use of teriparatide, an osteo-anabolic compound normally used for osteoporosis, in the spine. Species is not specified, as the review covers both preclinical and human clinical studies. The authors discuss its use for improving bone quality, fracture union, and fusion rate after spinal fusion, focusing on intermittent administration following instrumented spinal arthrodesis and its reported impact on spinal bone quality and spinal bone mineral density.
Abstract
Teriparatide belongs to osteo-anabolic compounds and has been used in recent years to treat patients with osteoporosis, with the benefits of increased bone density. Its osteo-anabolic action has led to the investigation of the use of teriparatide for the improvement of bone quality. Apart from the enhancement of fracture union, teriparatide has been extensively studied in the promotion of fusion rate after spinal fusion. This study summarizes the preclinical and clinical results of the off-label use of teriparatide in the spine, and specifically its intermittent administration after instrumented spinal arthrodesis along with its impact on the spinal bone quality and spinal bone mineral density.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.